Attached files
| file | filename |
|---|---|
| 10-Q - KERYX BIOPHARMACEUTICALS INC | v165354_10q.htm |
| EX-32.2 - KERYX BIOPHARMACEUTICALS INC | v165354_ex32-2.htm |
| EX-31.2 - KERYX BIOPHARMACEUTICALS INC | v165354_ex31-2.htm |
| EX-31.1 - KERYX BIOPHARMACEUTICALS INC | v165354_ex31-1.htm |
Exhibit
32.1
STATEMENT
OF CHIEF EXECUTIVE OFFICER OF
KERYX
BIOPHARMACEUTICALS, INC.
PURSUANT
TO 18 U.S.C. SECTION 1350,
AS
ADOPTED PURSUANT TO
SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002
In
connection with the quarterly report of Keryx Biopharmaceuticals, Inc. (the
“Company”) on Form 10-Q for the period ended September 30, 2009 as filed with
the Securities and Exchange Commission (the “Report”), I, Ron Bentsur, Chief
Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as
adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, based on my
knowledge:
1) The
Report fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and
2) The
information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the Company.
|
Date:
November 10, 2009
|
/s/ Ron
Bentsur
|
|
Ron
Bentsur
Chief
Executive Officer
Principal
Executive Officer
|